The Atypical HUS Foundation

aHUS Complications: Potential Impact for Multiple Organs

 Atypical HUS - It's Not Just About Kidneys

      The topic of aHUS complications has surfaced in multiple commentary, including aHUS community discussions that have referred to potential effects of aHUS damage that impact other vital organs and patient health.  Multi-organ involvement is referenced by multiple researchers, and patients/families/medical personnel may access such information via links here as a starting point to further explore the topic.  Provided via aHUS Source, a website provided by Alexion Pharmaceuticals (makers of Soliris, or eculizumab), you'll find "aHUS Clinical Complications" which notes among its information that  48% of aHUS patients experience neurological symptoms, 43% of aHUS patients experience problems with their cardiovascular systems, and about 30% of patients experience complications associated with the digestive system such as an inflamed colon, abdominal pain, or other issues involving the digestive tract.  This information is accompanied by solid citations from specific research studies and also from articles in medical journals by noted aHUS clinicians and investigators. (Source)  


     Patients with atypical HUS may experience damage throughout the body, not just the kidneys, with possible damage to such vital organs as the heart, bowel, or brain.  A visual representation that kidney issues are just 'the tip of the iceberg' regarding multi-organ involvement is noted by by a graphic at aHUS Source .  Visitors to Alexion’s aHUS Source site are encouraged to view the compilation of sources cited by Alexion as they note, " ....see the references used in outlining early symptoms, please view our reference list. " where they've made available in a comprehensive list of international references specific to aHUS research. 


     Those interested in further details regarding this particular atypical HUS info, Soliris (eculizumab), or Alexion's website (including Alexion's other site may contact 1-888-SOLIRIS for further information.  The Foundation for Atypical HUS (as well as this website) is an independent organization that strongly suggests that atypical HUS patients and their families connect with their own physicians and treatment teams to determine what is in the patient's best interests given each individual's status regarding disease diagnosis, treatments, and situation.


On June 17, 2012 Alexion Pharmaceuticals released a Business Wire titled : "New Data Show Majority of Patients with aHUS Experienced Systemic Multi-Organ Complications Prior to Treatment" viewable on their corporate website at


ASH Conference 2013

Abstract 2184: “Biomarkers of Complement and Endothelial Activation, Inflammation, Thrombosis, and Renal Injury in Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Treated with Eculizumab,” Cofiell, et al.

Accessible at:


Research Article:

Extra-renal manifestations of complement-mediated thrombotic microangiopathies

Hofer et al., Frontiers in Pediatrics (Sept. 2014) reviews published data on aHUS manifestations in organs other than the kidney, and suggests screening.  Thanks to Grace for providing this information to the aHUS community.





Views: 801

Reply to This

Replies to This Discussion

I found the symptom checker on the Alexion website to take to our next appointment. It highlights the low level symptoms my son has been experiencing including a puffy face and hopefully the Drs will understand my concerns that he is experiencing low level compliment activity.
Thanks for the info Linda

I just added a recently published paper (open access, Hofer et al., Frontiers in Pediatrics 2014) to the research forum which reviews published data on aHUS manifestations in organs other than the kidney, and suggests screening. Organ involvement can be subtle or challenging to diagnose, and possibly under-diagnosed and under-reported. So we need more awareness and better biomarkers, but at least we seem to moving toward those goals!

Reply to Discussion



To ensure proper processing of your membership, please make sure to set your email filters to accept emails, from

The Atypical HUS Foundation is an all-volunteer organization. Please allow at least 72 hours for an email response confirming your membership request.  If you do not receive an email, please check your spam folder or email directly to

Membership is open to patients, family, friends, caregivers research and medical personnel.


The Atypical HUS Foundation encourages patients and investigators to share information and explore options/resources as we work together to gain insight into this rare complement disorder. By increasing contact opportunities with researchers and medical personnel interested in helping the aHUS community, our stories foster a better understanding of atypical hemolytic uremic syndrome.

Sharing information, inspiration and support for one another, we seek to gather together people and knowledge as we strive to improve the lives of patients and families dealing with a diagnosis of aHUS.

Be proactive! Get the medical basics of aHUS, what lab values to monitor, and areas of concern...check out the "aHUS Bootcamp" and "About aHUS" tabs at the top of this page!
If your doctor has never treated a case of aHUS, please print out our 'Doc to Doc Registry' and ask him/her to contact a physician versed in the complexities of aHUS and new options for 2011 genetic testing and treatment.


NOTE: Our 'Send a Message" function on each Member's page allows for private discussion of personal content. As with any social network, be cautious about giving personal contact information (home email info, phone number) until you have an established relationship with another person, organization, or associated website.


Did you know...

CFH (Serum Complement Factor H) is a regulatory protein. The secreted protein product of CFH consists of 20 repetitive units named "short consensus repeats" or SCRs (each approximately 60 amino acids). In patients with aHUS the last 5 "pearls" in the twenty pearl strand protein, SCR16 - SCR20, should bind to protect cells but do not- they are defective in one or more of the last 5 SCR locations. If they cannot bind or stick to the kidney to protect that tissue, the platelets clump into clots that affect the glomeruli of the kidney -potentially causing acute renal failure.
• • • • • • • • • • • •
It is estimated that there are about 2 cases of aHUS in the U.S. per 1,000,000 of population, and about 60% of aHUS patients are diagnosed as children. The condition is potentially life threatening, and either can be chronic or can recur at intervals.
more factoids...

Help us fight the battle

Your donation of $295.for an aHUS pearl bracelet will directly fund research to help aHUSpatient and their families. Each bracelet has an appraised value of $925, and is offered with your gift of $295. Note:  For shipping outside the USA, please add $25. to cover international shipping costs.

(Note: Bracelets do not qualify as tax deductible donations under IRS regulations.)

Normally, aHUS pearl bracelets to be made-to-order and as such expect a 4 to 6 week window before your custom bracelet is shipped.  In a rush?  Contact with your request and details.


 Donations of a specific dollar amount are welcome-every dollar will help aHUS research efforts supported by The Atypical HUS Foundation at

Donations may be made via credit card or Paypal. If you prefer, checks made payable to The Atypical HUS Foundation may be mailed to:

The Atypical HUS Foundation
C/O Deborah Lewis
PO Box 333
Barnhart, MO 63012

For pearl bracelet orders, please allow extra time for processing checks. Questions about aHUS donations? Please email



© 2017   Created by Deborah Lewis.   Powered by

Badges  |  Report an Issue  |  Terms of Service